8-K: Karyopharm Reports Mixed 2023 Results, Anticipates Key Clinical Data in 2025

Karyopharm Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting a decrease in XPOVIO sales but anticipating key clinical trial readouts in 2025.

Summary

• Karyopharm Therapeutics reported a total revenue of $146 million for 2023, with U.S. XPOVIO net product revenue reaching $112 million, meeting the company's guidance.
• However, XPOVIO sales decreased from $120.4 million in 2022 to $112 million in 2023, with a fourth-quarter revenue of $25.1 million compared to $31.1 million in the same period of 2022.
• The company anticipates top-line data readouts from three pivotal Phase 3 trials for selinexor in endometrial cancer, myelofibrosis, and multiple myeloma in 2025.
• Karyopharm projects total revenue between $140 million and $160 million for 2024, including U.S. XPOVIO net product revenue between $100 million and $120 million.
• The company's cash runway is expected to extend into late 2025.
• R&D expenses for 2023 were $138.8 million, a decrease from $148.7 million in 2022, while SG&A expenses were $131.9 million, down from $145.4 million in the previous year.
• The net loss for 2023 was $143.1 million, or $1.25 per share, compared to a net loss of $165.3 million, or $2.02 per share, in 2022.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive clinical trial progress but declining revenue and a net loss. The company's cash runway is a positive, but the competitive landscape and financial challenges temper the overall sentiment.

Positives

• Karyopharm met its 2023 revenue guidance for XPOVIO.
• The company has a cash runway into late 2025.
• There is encouraging long-term data from the Phase 1 trial of selinexor with ruxolitinib in myelofibrosis.
• Selinexor use is shifting to earlier lines of therapy.
• New patents for selinexor were issued, extending intellectual property protection.
• The company has a clinical trial collaboration with Bristol Myers Squibb.

Negatives

• XPOVIO net product revenue decreased from $120.4 million in 2022 to $112 million in 2023.
• Fourth-quarter XPOVIO revenue decreased to $25.1 million from $31.1 million in the same period of 2022.
• Increased utilization of the Patient Assistance Program and higher discounts impacted XPOVIO revenue.
• XPOVIO sales were adversely impacted in the academic setting due to increased competition.
• The company reported a net loss of $143.1 million for 2023.

Risks

• Increased competition in the multiple myeloma space is impacting XPOVIO sales.
• The company is reliant on the success of its clinical trials, particularly the three Phase 3 trials expected to report in 2025.
• There is a risk of delays in clinical trial enrollment and reporting of results.
• The company's financial performance is dependent on the commercial success of XPOVIO and its ability to secure regulatory approvals.
• The company faces risks related to the adoption of XPOVIO in the commercial marketplace.
• There are risks associated with the company's ability to obtain, maintain, and enforce patent protection.

Future Outlook

Karyopharm anticipates key clinical data readouts in 2025 and expects total revenue between $140 million and $160 million for 2024, with a cash runway into late 2025.

Management Comments

• Richard Paulson, President and Chief Executive Officer of Karyopharm, stated that the company made significant progress in 2023 across its clinical pipeline and continued to build on its foundation in the multiple myeloma space.
• He also mentioned that the encouraging clinical results presented last year reinforce the potential of the three ongoing pivotal Phase 3 trials.
• Management is enthusiastic about the upcoming top-line read-outs from these trials and what they could mean for patients and selinexor's growth potential.

Industry Context

Karyopharm operates in the competitive oncology market, particularly in multiple myeloma, where it faces challenges from other therapies. The company is focusing on shifting selinexor use to earlier lines of therapy and exploring combinations with other agents to maintain its position.

Comparison to Industry Standards

• Karyopharm's XPOVIO revenue decline highlights the competitive pressures in the oncology market, where new therapies and generic alternatives can quickly impact sales. For example, companies like Celgene (now part of Bristol Myers Squibb) with Revlimid and Pomalyst, and Johnson & Johnson with Darzalex, have established strong positions in the multiple myeloma space, creating a challenging environment for XPOVIO.
• The company's focus on Phase 3 trials is similar to other biotech companies aiming to expand their drug's indications and market share. For example, companies like Exelixis with Cabometyx and Incyte with Jakafi have successfully expanded their labels through positive Phase 3 results.
• Karyopharm's collaboration with Bristol Myers Squibb is a common strategy in the industry to explore combination therapies and leverage the expertise of larger pharmaceutical companies. This is similar to collaborations seen between companies like Merck and Eisai, or Pfizer and Myovant, where they combine their respective drugs to improve patient outcomes.
• The company's cash runway into late 2025 is a critical factor, as many biotech companies rely on capital raises to fund their operations and clinical trials. Companies like BioMarin and Vertex have demonstrated the importance of maintaining a strong cash position to support their research and development efforts.

Stakeholder Impact

• Shareholders may be concerned about the decrease in XPOVIO revenue and the net loss, but encouraged by the clinical trial progress and cash runway.
• Employees may be affected by the company's cost-cutting measures, including reductions in personnel costs.
• Patients may benefit from the potential approval of selinexor in new indications.
• Customers may experience changes in the availability and pricing of XPOVIO due to increased competition and discounts.
• Suppliers may be impacted by changes in the company's spending and clinical trial activities.
• Creditors may be concerned about the company's financial performance and ability to repay debts.

Next Steps

• Present updated exploratory subgroup analysis results in patients with TP53 wild-type EC from the Phase 3 SIENDO trial in 2024.
• Complete enrollment in pivotal XPORT-EC-042 Phase 3 trial in TP53 wild-type EC in 2H 2024 and report top-line results in 1H 2025.
• Report updated results from the Phase 1 trial of selinexor in combination with ruxolitinib in patients with treatment-nave MF in 2024.
• Report preliminary results from the Phase 2 trial evaluating the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-nave MF and moderate thrombocytopenia in 2H 2024.
• Report top-line results from pivotal Phase 3 trial of selinexor in combination with ruxolitinib in treatment-nave MF in 2H 2025.
• Publish and present efficacy and safety data on selinexor 40mg in combination with pomalidomide and dexamethasone from ongoing STOMP/028 Phase 2 trials in patients with MM in 2024.
• Report additional data on selinexor's impact on T-cell fitness and potential combinability with multiple agents preor post-T-cell therapy in patients with MM in 2024.
• Complete enrollment in pivotal Phase 3 trial evaluating an oral combination of 40mg selinexor, pomalidomide and dexamethasone in patients with previously treated MM in 2H 2024 and report top-line results in 1H 2025.
• Maintain the Company's commercial foundation in the competitive MM marketplace, driving increased XPOVIO revenues.
• Continue global launches and reimbursement approvals for selinexor by partners in ex-U.S. territories.

Key Dates

Keywords

selinexor, XPOVIO, Karyopharm, multiple myeloma, endometrial cancer, myelofibrosis, clinical trials, revenue, pharmaceutical, cancer therapy